TCW Fund Exits Teva After Shares Outgrow Its Valuation Tests
The fund cited Teva’s share appreciation, branded-drug growth and improved margins as it explained its second-quarter exit.
Makkler Newsroom · Oct 1, 04:35 PM · 1 min read
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.